AzTrials
AzTrials

Pancreatic CancerPhase 4SPARROWNCT05784311

Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)

A Phase 4 study testing Cefuroxime and Metronidazole in people with Pancreatic Cancer, run by Leiden University Medical Center at 11 sites in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Pancreatic Cancer
What is being tested?
Cefuroxime and Metronidazole
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
344 participants
Where
11 sitesNetherlands
Study dates
6 Mar 2023to Jan 2026
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients undergoing elective pancreatoduodenectomy with a high risk for contaminated bile defined as patients with preoperative biliary drainage or an ampullary malignancy.
  • Age >18 years

Who cannot join

  • Pregnancy
  • Contraindication for the study antibiotics (e.g. allergy or intolerance)
  • Preoperative planned therapeutic antibiotic treatment (i.e. for cholangitis or liver abscesses)
  • A reduced renal function, defined as an eGFR of <60 ml/min/1.73m2 measured on the closest timepoint prior to pancreatoduodenectomy

Trial locations and contacts

11 sites in 1 country.

Daphne HM Droogh, MD contact

071 5261334

d.h.m.droogh@lumc.nl

11 sites in 1 country

Netherlands11 sites, 11 recruiting
  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch

    Koop Bosscha, MD

    Not yet recruiting
  • Amsterdam University Medical Center

    Amsterdam

    Marc GH Besselink, Prof. Dr

    Marc GH Besselink, Prof. Dr.

    Recruiting
  • Amphia Ziekenhuis

    Breda

    Jan H Wijsman, MD PhD

    Recruiting
  • Catharina Ziekenhuis

    Eindhoven

    Misha DP Luyer, MD PhD

    Recruiting
  • Medisch Spectrum Twente

    Enschede

    Daan J Lips, MD PhD

    Recruiting
  • Groningen University Medical Center

    Groningen

    Frederik JH Hoogwater, MD PhD

    Recruiting
  • Leiden University Medical Center

    Leiden, South Holland, 2333 ZA

    Daphne HM Droogh, MD, 071 5261334, d.h.m.droogh@lumc.nl

    Daphne HM Droogh, MD

    Recruiting
  • Maastricht University Medical Center

    Maastricht

    Stefan AW Bouwense, MD PhD

    Recruiting
  • Radboud University Medical Center

    Nijmegen

    Martijn Stommel, MD PhD

    Recruiting
  • Erasmus MC Cancer Institute

    Rotterdam

    Bas Groot Koerkamp, Prof. Dr.

    Recruiting
  • Regional Academic Cancer Center Utrecht

    Utrecht

    Hjalmar C van Santvoort, Prof. Dr

    Hjalmar C van Santvoort, Prof. Dr.

    Recruiting

Other trials in Netherlands

About this study

Official title: Standard Versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes After Whipple's Procedure (SPARROW): a Multicenter, Randomized Controlled Trial

The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. The main objectives it aims to answer are:

  • To evaluate the effect of pre-emptive antibiotic prophylaxis on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile
  • To evaluate the effect of pre-emptive antibiotic prophylaxis on other postoperative outcomes (e.g. OSIs, superficial SSIs, POPF, PPH, major morbidity, ICU admission, readmission, length of hospital stay, and mortality).
  • To evaluate concordance between perioperatively obtained bile cultures and postoperative cultures from infectious sites, and to evaluate antibiotic sensitivity patterns of the cultured microorganisms.
Read more

Participants will be randomized with a 1:1 allocation before surgery into the intervention or control group:

  • Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily.
  • Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
Read the detailed description

Rationale: The additional value of pre-emptive antibiotic treatment after pancreatoduodenectomy is undetermined as previous research reported conflicting results regarding infectious complications. Prolonged antibiotic prophylaxis (formally pre-emptive antibiotic treatment) after pancreatoduodenectomy might reduce the rate of surgical site infections in patients with a high risk for contaminated bile (predominantly patients with preoperative biliary drainage or an ampullary malignancy). Current national and international guidelines lack clear recommendations regarding pre-emptive antibiotic treatment leading to substantially varying antibiotic prophylactic regimes between institutes.

Objective: This trial evaluates the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile.

Study design: This multicenter, randomized controlled, superiority trial compares perioperative versus pre-emptive antibiotic treatment during five postoperative days after pancreatoduodenectomy in patients with a high risk for contaminated bile.

Study population: Adult patients undergoing pancreatoduodenectomy with a high risk for contaminated bile (patients with preoperative biliary drainage or an ampullary malignancy). Patients with a contraindication for the study antibiotics or a preoperative indication for antibiotics (e.g. cholangitis of preoperative abscesses) are excluded.

Intervention: Participants will be randomized to either perioperative prophylaxis (cefazolin, metronidazole and a single dose of 5-7mg/kg gentamicin, control arm) or additional cefuroxime and metronidazole for five postoperative days (experimental arm).

Main study endpoints: The primary endpoint are organ/space infections (OSIs) within 90 days after surgery requiring a therapeutic intervention. Secondary endpoints are OSIs, isolated OSIs, wound infections, postoperative pancreatic fistula, bile or enteric anastomotic leakage, post pancreatectomy hemorrhage, delayed gastric emptying, bacteremia, Clostridium difficile infection, major morbidity (Clavien-Dindo ≥III), reintervention, ICU admission, length of hospital stay, readmission, and in-hospital and 90-day mortality. Besides, switch of postoperative antibiotics, antibiotic sensitivity patterns and concordance between perioperative bile and postoperative surgical site cultures are analyzed.

Sample size: The sample size is calculated for superiority to achieve an OSI difference of 15% (40% vs 25%). With a 80% power (1-β) and a two-sided significance level (α) of 5.0%, a sample of 304 evaluable patients is required for superiority. Assuming a 3% non-resection rate due to metastatic disease and a 3% loss-of-follow-up rate, an expected number of 322 included patients are needed to reach the sample size of 304 evaluable patients to demonstrate superiority for the intervention.

Being tested
Cefuroxime, Metronidazole
Keywords
Antibiotic prophylaxis, Preoperative biliary drainage, Surgical site infection
Medical subject headings
Pancreatic Neoplasms, Surgical Wound Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CefuroximeDrug

    Also called Zinacef

    1500mg IV cefuroxime thrice daily during five days.

  • MetronidazoleDrug

    Also called Flagyl

    500mg IV metronidazole thrice daily during five days.

Study groups in NCT05784311
Study groupRoleWhat they receive
Perioperative plus prolonged antibiotic prophylaxisExperimentalProlonged prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery (perioperative prophylaxis) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily
Receives: Drug: Cefuroxime; Drug: Metronidazole
Only perioperative prophylaxisNo interventionPerioperative prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of clinically relevant organ/space surgical site infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis

    A clinically relevant OSI is defined by the following criteria:

    • A deep surgical site infection involving any part of the abdomen (e.g. organs and/or spaces) other than the surgical incision within 90 days after surgery.
    • AND Requires radiological, endoscopic or surgical intervention OR therapeutic antibiotics required for an episode of sepsis, defined as two or more SIRS criteria.
    • AND Organisms isolated from an aseptically obtained culture.

    Measured: 90 days after surgery

Secondary outcomes (15)
  1. The rate of organ/Space Infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis

    An OSI is defined by the CDC definition:

    • The infection appears to be related to the operative procedure and infection involves any part of the anatomy (e.g., organs or spaces) other than the incision opened or manipulated during the operative procedure, and at least one of the following is present:
    1. Purulent drainage from a drain that is placed into the organ/space.
    2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space.
    3. An abscess or other evidence of infection involving the organ/space on direct examination, during reoperation, or by histopathologic or radiologic examination.
    4. Diagnosis of an organ/space SSI by a surgeon or attending physician."

    Measured: 90 days

  2. The rate of isolated OSI between patients with perioperative versus prolonged antibiotic prophylaxis

    Isolated OSI is defined as an OSI without concurrent anastomotic leakage (pancreatojejunostomy, hepaticojejunostomy or gastrojejunostomy). The concept of an isolated OSI is used to separately classify abdominal infections without concurrent anastomotic leakage.

    Measured: 90 days

  3. The rate of superficial incisional SSI between patients with perioperative versus prolonged antibiotic prophylaxis

    A superficial surgical site infection after surgery which involves superficial or deep soft tissue (skin, muscle or fascia, but no intra-abdominal tissue), and at least one of the following criteria is present:

    • Purulent drainage from the incision or subcutaneous tissue.
    • Isolation of microorganisms from an aseptically obtained culture of fluid or tissue from the superficial incision of subcutaneous tissue.
    • Superficial infections of the skin or subcutaneous tissue which is deliberately opened by a surgeon or attending physician OR at least one of the following signs are present: localizes pain, tenderness, swelling, heat or fever >38 degrees).

    Measured: 90 days

  4. The rate of clinically relevant postoperative pancreatic fistula between patients with perioperative versus prolonged antibiotic prophylaxis

    Grade B or C postoperative pancreatic fistula (POPF) defined by the International Study Group of Pancreatic Surgery definition:

    Grade A: Amylase >3 times upper limit of the institutional normal serum amylase value

    Grade B: Grade A + persistant drainage >3 weeks, clinically relevant change in management of POPF, percutaneous or endoscopic drainage, angiographic procedures for bleeding, or signs of infection without organ failure.

    Grade C: Grade A or B requiring reoperation, resulting in organ failure or death.

    Measured: 90 days

  5. The rate of bile leakage between patients with perioperative versus prolonged antibiotic prophylaxis

    Grade A, B or C defined by the ISGLS definition:

    Grade A: Bile leakage requiring no or little change in patients' clinical management.

    Grade B: Bile leakage requiring a change in patients clinical management (eg, additional diagnostic or interventional procedures) but manageable without relaparotomy, or a Grade A bile leakage lasting for >1 week.

    Grade C: Bile leakage requiring relaparotomy

    Measured: 90 days

  6. The rate of post pancreatectomy hemorrhage between patients with perioperative versus prolonged antibiotic prophylaxis

    Grade A, B or C defined by the ISGPS definition:

    Grade A: Early (<24h after surgery), intra- or extraluminal, clinically mild.

    Grade B: Early (<24h after surgery), intra- or extraluminal and clinically severe OR later (>24h after surgery), intra- or extraluminal and clincally mild.

    Grade C: Late (>24h after surgery), intra- or extraluminal and clinically severe.

    Measured: 90 days

  7. The rate of delayed gastric emptying between patients with perioperative versus prolonged antibiotic prophylaxis

    Grade A, B or C defined by the ISGPS definition:

    Grade A: Until day 4-7 or replacement of feeding tube > 3 days after surgery

    Grade B: Until day 8-14 or replacement of feeding tube > 7 days after surgery

    Grade C: >day 14 or replacement of feeding tube > 14 after surgery

    Measured: 90 days

  8. The rate of postoperative bacteremia between patients with perioperative versus prolonged antibiotic prophylaxis

    Defined as a positive blood culture obtained during a septic period (defined as two or more SIRS criteria)

    Measured: 90 days

  9. The rate of Clostridium difficile infection between patients with perioperative versus prolonged antibiotic prophylaxis

    Defined by a positive fecal culture for Clostridium difficile

    Measured: 90 days

  10. Rate of major complications between patients with perioperative versus prolonged antibiotic prophylaxis

    Major complications is defined by a Clavien-Dindo score of ≥III.

    Clavien-Dindo classification of Surgical Complications:

    Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.

    Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications.

    Grade IIIa: Requiring surgical, endoscopic or radiological intervention not under general anesthesia Grade IIIb: Requiring surgical, endoscopic or radiological intervention under general anesthesia

    Grade IVa: Life-threatening complication (including CNS complications)* requiring IC/ICU-management with single organ dysfunction (including dialysis).

    Grade IVb: Life-threatening complication (including CNS complications)* requiring IC/ICU-management with multi organ dysfunction.

    Grade V: Death of a patient

    Measured: 90 days

  11. The number of reinterventions in patients with perioperative versus prolonged antibiotic prophylaxis

    Reinterventions could be either radiological, surgical or endoscopic reinterventions

    Measured: 90 days

  12. The number of ICU admission in patients with perioperative versus prolonged antibiotic prophylaxis

    ICU admission

    Measured: 90 days

  13. Length of hospital stay in patients with perioperative versus prolonged antibiotic prophylaxis

    In days

    Measured: 90 days

  14. The number of readmissions between patients with perioperative versus prolonged antibiotic prophylaxis

    Readmission into the hospital

    Measured: 90 days

  15. Mortality

    In-hospital and 90-days mortality

    Measured: 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2023
  2. Study start6 Mar 2023
  3. Primary completionJul 2025 (estimated)
  4. Study completionJan 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients will be randomized with a 1:1 allocation before surgery into the intervention or control group: * Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily. * Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.
Masking
None (open label)
Enrolment
344 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05784311
Sponsor's protocol ID
NL82304.058.22
Acronym
SPARROW
Status last verified
Oct 2024
First submitted
27 Feb 2023
Last updated
21 Oct 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Available upon request to the principal investigator

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Cefuroxime and Metronidazole in people with Pancreatic Cancer, run by Leiden University Medical Center at 11 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 11 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Daphne HM Droogh, MD (071 5261334, d.h.m.droogh@lumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of clinically relevant organ/space surgical site infection (OSI) between patients with perioperative versus prolonged antibiotic prophylaxis (time frame: 90 days after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in